Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension

NCT02169752 is registered in ClinicalTrials.gov with National Jewish Health as lead sponsor.

NCT NCT02169752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02169752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
Lead sponsor
National Jewish Health
Phase
Not applicable
Overall status
Terminated
Start date
September 30, 2012
Completion date
May 25, 2017
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pre-pulmonary atrial hypertension